
Kopran Q3 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
No
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Target to grow to around INR1,200 crores in the next 3 years through new products and volume increase.
- Expect 10%-12% growth in API segment next year, and about 20% growth in the following year.
- Consolidated sales growth expected around 15% for FY '26 and 20% for FY '27.
- Expansion in CMO and CDMO projects to contribute significantly; aiming for over 50% of business from these in 2 years.
- Increased market share in key products like Meropenem (around 20% contribution currently).
- Capacity expansions underway at Panoli and Mahad plants to meet increasing demand, with Panoli expected to stabilize next year.
- Moving towards higher-margin regulated market projects for sustainable growth and profitability.
- Pricing pressure from Chinese competition is stabilizing, with volume growth helping offset price erosion.
See what Kopran management said on margin guidance — free account, 30 seconds.
Fundraise plans
NoSee what Kopran management said on order book — free account, 30 seconds.
Capex plans
Yes- For the next 1 to 2 years, Kopran Limited does not foresee very large capex, except possibly for setting up vial filling for penems.
- Existing capacity is considered sufficient to meet expected demand for the next 2 to 3 years.
- In FY '23 and '24, capex was around INR 60 crores each year; capex is expected to significantly reduce in the next couple of years.
- Additional capex may be needed if existing projects under consideration materialize and demand increases, requiring dedicated plants.
- For formulation businesses, capex remains moderate, around INR 10 crores over 9 months.
- The Panoli plant capex is largely completed; commercial production expected to start in Q1 FY '26.
- The company is also investing in expanding capacities for growing products like Faropenem and CMO/CDMO projects, which have better margins.
Track Kopran — get its next earnings analysis in your feed
How does Kopran rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Kopran rank in Pharmaceuticals & Biotechnology?
Compare Kopran against every Pharmaceuticals & Biotechnology company (Q3 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Kopran's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem